159 related articles for article (PubMed ID: 37714257)
1. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular.
Li O; Li L; Sheng Y; Ke K; Wu J; Mou Y; Liu M; Jin W
Cancer Lett; 2023 Oct; 574():216391. PubMed ID: 37714257
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
4. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
5. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
6. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
7. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
8. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
9. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
[TBL] [Abstract][Full Text] [Related]
10. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
13. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
[TBL] [Abstract][Full Text] [Related]
14. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
15. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
16. Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28.
Zhang S; Li P; Li J; Gao J; Qi Q; Dong G; Liu X; Jiao Q; Wang Y; Du L; Zhan H; Xu S; Wang C
Br J Cancer; 2023 Aug; 129(3):426-443. PubMed ID: 37380804
[TBL] [Abstract][Full Text] [Related]
17. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment.
Bhatia R; Bhyravbhatla N; Kisling A; Li X; Batra SK; Kumar S
Semin Cancer Biol; 2022 Nov; 86(Pt 2):499-510. PubMed ID: 35346801
[TBL] [Abstract][Full Text] [Related]
18. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
19. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
20. Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis.
Costamagna A; Natalini D; Camacho Leal MDP; Simoni M; Gozzelino L; Cappello P; Novelli F; Ambrogio C; Defilippi P; Turco E; Giovannetti E; Hirsch E; Cabodi S; Martini M
Gastroenterology; 2022 Apr; 162(4):1242-1255.e11. PubMed ID: 34922945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
